HekaFlo

HekaFlo high-flow nasal cannula oxygen therapy (HFNC) device is an innovative respiratory support system for the treatment of spontaneously breathing hypoxic patients with 100% humidified and heated oxygen at a flow rate of up to 60 LPM. This treatment is highly effective for patients with Post-COVID complications having difficulty in breathing or shortness of breath.

HFNC is an effective and safe initial respiratory support treatment in children less than two years with mild to moderate respiratory failure due to pneumonia.

Key benefits of HekaFlo oxygenation therapy

The flow rate for traditional oxygen therapy is up to 15 liters per minutes and HFNO based high flow oxygen therapy is up to 60 L/min. According to American Journal of Respiratory and Critical Care Medicine, this newer mode of delivering supplemental oxygen at high flows (40–60 L/min) permits high FiO2; the gas is heated and humidified to avoid mucosal injury and patient discomfort, overcoming the key problems of past use of high flow rates.